Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 9/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863220 | 1.00 | HCAR3 (0.49) | HCAR3HCAR2HIPK2MEN1KMT2A | |
| SCHEMBL3854717 | 0.88 | HCAR3 (0.40) | HCAR3HIPK2KMT2AALDH1A1HSD17B10 | |
| SCHEMBL3854720 | 0.88 | HCAR3 (0.40) | HCAR3HIPK2KMT2AALDH1A1HSD17B10 | |
| SCHEMBL3854438 | 0.80 | HCAR3 (0.46) | HCAR3HCAR2HIPK2MEN1KMT2A | |
| SCHEMBL3854437 | 0.80 | HCAR3 (0.46) | HCAR3HCAR2HIPK2MEN1KMT2A | |
| SCHEMBL3858368 | 0.80 | HCAR3 (0.51) | HCAR3HCAR2HIPK2MEN1KMT2A | |
| SCHEMBL3858369 | 0.80 | HCAR3 (0.51) | HCAR3HCAR2HIPK2MEN1KMT2A | |
| SCHEMBL3855136 | 0.80 | HCAR3 (0.54) | HCAR3HCAR2HIPK2MEN1KMT2A | |
| SCHEMBL3856987 | 0.76 | HCAR3 (0.50) | HCAR3HCAR2HIPK2MEN1KMT2A | |
| SCHEMBL3856989 | 0.76 | HCAR3 (0.50) | HCAR3HCAR2HIPK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-7585885-B2 | Pyrrolidine derivatives useful as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | ELI LILLY AND COMPANY | 2007-09-13 | — | — | US | disclosed |
| EP-1740575-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005108358-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | HCAR3 1734/4885HCAR2 984/4885HIPK2 3718/4885 |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | BACE1, BACE2, PSEN1 | HCAR3 3196/4885HCAR2 2416/4885HIPK2 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.